A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity

Article Tools

• Email

  Thank you for your interest in spreading the word about Science Translational Medicine.

  NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

  Your Email

  Your Name

  Send To

  Enter multiple addresses on separate lines or separate them with commas.

  You are going to email the following A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity

  Message Subject (Your Name) has forwarded a page to you from Science Translational Medicine

  Message Body (Your Name) thought you would like to see this page from the Science Translational Medicine web site.

  Your Personal Message

  Send Message
• Download Powerpoint
• Print
• Alerts

  Please log in to add an alert for this article.

  Log In with your AAAS ID

  Sign In to Email Alerts with your Email Address

  Email

  Log in
• Citation tools

  A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity

  By Jodi L. Karnell, Marius Albulescu, Stacey Drabic, Liangwei Wang, Rachel Moate, Manuel Baca, Vaheh Oganesyan, Michele Gunsior, Thomas Thisted, Li Yan, Jing Li, Ximing Xiong, Steven C. Eck, Melissa de los Reyes, Isharat Yusuf, Katie Streicher, Ulf Müller-Ladner, David Howe, Rachel Ettinger, Ronald Herbst, Jörn Drappa

  Science Translational Medicine24 Apr 2019

  VIB4920, a nonantibody scaffold protein, blocks CD40L and reduces autoantibodies and disease activity in patients with rheumatoid arthritis.

  • Supplementary Materials

  Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
• Share

  A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity

  By Jodi L. Karnell, Marius Albulescu, Stacey Drabic, Liangwei Wang, Rachel Moate, Manuel Baca, Vaheh Oganesyan, Michele Gunsior, Thomas Thisted, Li Yan, Jing Li, Ximing Xiong, Steven C. Eck, Melissa de los Reyes, Isharat Yusuf, Katie Streicher, Ulf Müller-Ladner, David Howe, Rachel Ettinger, Ronald Herbst, Jörn Drappa

  Science Translational Medicine24 Apr 2019

  VIB4920, a nonantibody scaffold protein, blocks CD40L and reduces autoantibodies and disease activity in patients with rheumatoid arthritis.

  • Supplementary Materials

  Share This Article: Copy